Products for Research Use Only
RegisterLogin

Ursodeoxycholic acid-d4

CAT: 0804-HY-113478S-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-113478S-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid. Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno) deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
CAS Number
347841-46-7
Product Name Alternative
Ursodeoxycholate-d4; Ursodiol-d4; UDCA-d4
UNSPSC
12352211
Hazard Statement
H302-H315-H319-H335
Target
Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Others
Field of Research
Infection; Metabolic Disease
Purity
99.52
Solubility
10 mM in DMSO|DMF : ≥ 10mg/mL|DMSO : ≥ 10mg/mL|Ethanol : ≥ 1mg/mL
Smiles
C[C@@]12[C@]([C@]3([C@@]([C@]4(C)[C@](C[C@@H]3O)(C([C@H](O)C(C4)([2H])[2H])([2H])[2H])[H])(CC1)[H])[H])(CC[C@@]2([C@@H](CCC(O)=O)C)[H])[H]
Molecular Formula
C24H36D4O4
Molecular Weight
396.60
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Jackson H, et al. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology. 2007 Oct;46 (4) :1131-7.|[3]Kumar D, et al. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16 (1) :3-14.|[4]Biao Nie, et al. Specific Bile Acids Inhibit Hepatic Fatty Acid Uptake in Mice. Hepatology. 2012 Oct;56 (4) :1300-10.|[5]Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022 Dec 5.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-W752912Tauro-d4-ursodeoxycholic acid
HY-13771-01Ursodeoxycholic acid
HY-13771R-01Ursodeoxycholic acid (Standard)
HY-13771S1-01Ursodeoxycholic acid-13C
HY-113478-013β-Ursodeoxycholic acid
HY-13771A-01Ursodeoxycholic acid (sodium)
HY-113478R-013β-Ursodeoxycholic acid (Standard)
HY-W6998133β-Ursodeoxycholic acid-d5
HY-149754Ursodeoxycholic acid 7-N-acetylglucosaminide
HY-132686S-01Ursodeoxycholic acid methyl ester-d5

Alternative Products

CatalogName
TRC-U850007-1MGUrsodeoxycholic Acid-d4
ESS0313-01Ursodeoxycholic Acid D4
468513-01Ursodeoxycholic Acid-d4 (Major)
TRC-U850006-100MG3beta-Ursodeoxycholic Acid-d4
TRC-T779312-10MGTauro-d4-ursodeoxycholic Acid
ESS0481-0124-Nor Ursodeoxycholic Acid-D4 (major)
TBZ2838Ursodeoxycholic acid

Popular Products